澤田 憲太郎 (サワダ ケンタロウ)

北海道大学病院 内科助教

研究者基本情報

■ URL
researchmap URLホームページURL■ ID 各種
研究者番号
  • 70815159
J-Global ID■ 研究キーワード・分野
研究分野
  • ライフサイエンス, 腫瘍診断、治療学, 腸内細菌叢
  • ライフサイエンス, 腫瘍診断、治療学, 個別化医療
  • ライフサイエンス, 消化器内科学, がん化学療法

経歴

■ 経歴
経歴
  • 2026年07月 - 現在
    北海道大学病院, 消化器内科, 助教
  • 2026年04月 - 2026年06月
    北海道大学病院, 消化器内科, 特任助教
  • 2020年04月 - 2026年03月
    独立行政法人労働者健康安全機構 釧路労災病院, 腫瘍内科, 部長
  • 2019年04月 - 2020年03月
    国立がん研究センター東病院, 消化管内科, 医員
  • 2018年04月 - 2019年03月
    北海道大学病院, 腫瘍センター, 医員
  • 2016年04月 - 2018年03月
    国立がん研究センター東病院, 消化管内科, がん専門修練医
  • 2015年04月 - 2016年03月
    北海道大学病院, 消化器内科, 医員
  • 2014年04月 - 2015年03月
    北見赤十字病院, 消化器内科
  • 2012年04月 - 2014年03月
    独立行政法人労働者健康安全機構 釧路労災病院, 内科
  • 2010年04月 - 2012年03月
    独立行政法人労働者健康安全機構 釧路労災病院, 初期研修医
学歴
  • 2015年04月 - 2019年03月, 北海道大学, 内科学講座消化器内科学教室, 博士課程
  • 2004年04月 - 2010年03月, 北海道大学病院, 医学部, 医学科

研究活動情報

■ 論文
  • A phase II trial of ramucirumab and docetaxel as second-line treatment for patients with advanced gastric cancer (HGCSG 1903)
    Yasuyuki Kawamoto; Kentaro Sawada; Kazuaki Harada; Iori Motoo; Takayuki Ando; Susumu Sogabe; Yoshimitsu Kobayashi; Masayoshi Dazai; Michio Nakamura; Kazuteru Hatanaka; Atsushi Ishiguro; Atsushi Sato; Shintaro Nakano; Yoshiaki Shindo; Ayumu Hosokawa; Ken Ito; Ayumu Yoshikawa; Akira Ueda; Kayoko Iuchi; Isao Yokota; Satoshi Yuki; Yoshito Komatsu
    Gastric Cancer, 29, 4, 808, 815, Springer Science and Business Media LLC, 2026年05月04日, [査読有り]
    英語, 研究論文(学術雑誌), Abstract

    Background

    Ramucirumab has shown efficacy in combination with paclitaxel in the second-line treatment of advanced gastric cancer (AGC). The efficacy and safety regarding the combination therapy of ramucirumab and docetaxel have not been reported. This treatment could reduce the incidence of neuropathy and patients’ hospital visits.

    Methods

    This was a multicenter, single-arm phase II trial. Patients with AGC who were refractory or intolerant to primary treatment were eligible. Patients received ramucirumab at a dose of 8 mg/kg on day1 and 15, and docetaxel at a dose of 60 mg/m 2 on day1 of a 28-day cycle. The primary endpoint was overall response rate (ORR). The secondary endpoints were progression-free survival (PFS), overall survival (OS), relative dose intensity, and safety.

    Results

    A final analysis of efficacy and safety was performed in 35 patients. ORR was 25.7% (90% confidence interval [CI] 14.1–40.6) and disease control rate was 74.3% (90%CI 59.4–85.9). Median PFS and OS were 3.1 months (95%CI 2.1–4.2) and 11.5 months (95%CI 9.2–13.9), respectively. Grade 3 or higher adverse events that occurred in more than 10% of patients were neutropenia, leucopenia, febrile neutropenia, hypertension, and anorexia. The study protocol was amended to allow primary granulocyte-colony stimulating factor (G-CSF) prophylaxis during study period. There was no one incident febrile neutropenia after the protocol amendment. Peripheral sensory neuropathy occurred in 65.7% of all grades, with no incidence of grade 3 or higher.

    Conclusions

    The combination therapy of ramucirumab and docetaxel demonstrated some efficacy for AGC. Caution is required regarding the occurrence of febrile neutropenia. This treatment might be considered as an option for second-line treatment of patients with AGC.
  • Gut microbiota diversity in patients with ESCC: associations with esophagectomy, the tumor immune microenvironment, and nivolumab response
    Yuho Ebata; Eiji Oki; Qingjiang Hu; Hirofumi Hasuda; Tetsuro Kawazoe; Sho Nambara; Yasuo Tsuda; Tomonori Nakanoko; Koji Ando; Yasue Kimura; Kentaro Sawada; Riu Yamashita; Satoshi Horasawa; Takao Fujisawa; Hideaki Bando; Yoshiaki Nakamura; Takayuki Yoshino; Haruka Yokota; Hiroshi Ohno; Tomoharu Yoshizumi
    Esophagus, 23, 3, 523, 534, Springer Science and Business Media LLC, 2026年04月20日, [査読有り]
    英語, 研究論文(学術雑誌)
  • Single‐Cell Analysis Identified a Recurrent Malignant‐Associated Transcriptional State in Colorectal Cancer
    Sadahiro Iwabuchi; Kentaro Sawada; Motohiro Kojima; Miho Ozawa; Hiroya Taniguchi; Hideaki Bando; Kazumi Abe; Yuta Kuze; Kiyomi Imamura; Yukie Kashima; Yoshihiko Hirohashi; Atsushi Tajima; Toshihiko Torigoe; Yutaka Suzuki; Takayuki Yoshino; Shinichi Hashimoto
    Cancer Science, 117, 5, 1397, 1411, Wiley, 2026年03月02日, [査読有り]
    英語, 研究論文(学術雑誌), ABSTRACT

    Colorectal cancer (CRC) exhibits substantial molecular heterogeneity, yet detailed single‐cell transcriptomic data from Japanese patients remain limited. Here, we performed single‐cell RNA sequencing (scRNA‐seq) on tumor tissues and adjacent normal tissues from four Japanese CRC patients to characterize malignant cell populations. We identified a common cancer‐associated cell cluster observed across all four cases, characterized by high expression of the long noncoding RNA KCNQ1 opposite strand/antisense transcript 1 ( KCNQ1OT1 ). Further analysis revealed a marked decrease in Ras Association Domain Family Member 6 ( RASSF6 ) expression within this cluster, despite clinical datasets reporting that elevated RASSF6 expression correlates with poor overall survival in Western cohorts. Reanalysis of publicly available bulk RNA‐seq data from independent East Asian cohorts confirmed that RASSF6 expression was consistently reduced in tumor tissues compared with adjacent normal colon tissues, while KCNQ1OT1 expression showed no apparent differences across cohorts. Collectively, our single‐cell analysis delineates a recurrent cancer‐associated transcriptional state observed within this cohort and highlights distinct gene expression features that may be underappreciated by bulk or population‐averaged analyses, underscoring the value of single‐cell profiling for refining molecular interpretations of CRC.
  • Predictors of the early discontinuation of anamorelin hydrochloride in gastrointestinal cancer-related cachexia: a multicenter retrospective cohort study (HGCSG2201)
    Kazuaki Harada; Shinya Kajiura; Kentaro Sawada; Kazuteru Hatanaka; Atsushi Sato; Ken Ito; Hotaka Tamura; Ayako Doi; Takayuki Ando; Michio Nakamura; Hiroshi Nakatsumi; Tetsuhito Muranaka; Susumu Sogabe; Takahiro Ishii; Shintaro Nakano; Masayoshi Dazai; Yusuke Sasaki; Yasuyuki Kawamoto; Satoshi Yuki; Yuh Sakata; Yoshito Komatsu
    Supportive Care in Cancer, 34, 3, Springer Science and Business Media LLC, 2026年02月19日, [査読有り]
    英語, 研究論文(学術雑誌)
  • Long-term outcome after endoscopic submucosal dissection for entire circumferential cT1aN0M0 esophageal squamous cell carcinoma
    Atsushi Inaba; Tomohiro Kadota; Keiichiro Nishihara; Daiki Sato; Keiichiro Nakajo; Hiroki Yukami; Saori Mishima; Kentaro Sawada; Daisuke Kotani; Hisashi Fujiwara; Masaki Nakamura; Hidehiro Hojo; Yusuke Yoda; Takashi Kojima; Takeo Fujita; Tomonori Yano
    Gastrointestinal Endoscopy, Elsevier BV, 2026年01月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial
    Daisuke Sakai; Shigenori Kadowaki; Ryohei Kawabata; Hiroki Hara; Hironaga Satake; Masazumi Takahashi; Atsushi Takeno; Hiroo Imai; Keiko Minashi; Takeshi Kawakami; Shogen Boku; Jin Matsuyama; Yasuhiro Sakamoto; Kentaro Sawada; Masato Kataoka; Hisato Kawakami; Toshio Shimokawa; Narikazu Boku; Taroh Satoh
    Journal of Clinical Oncology, 43, 19, 2196, 2207, American Society of Clinical Oncology (ASCO), 2025年07月, [査読有り]
    英語, 研究論文(学術雑誌), PURPOSE

    Continuous use of antiangiogenic agents has demonstrated survival benefits in various cancers. This trial aimed to compare the efficacy and safety of ramucirumab plus irinotecan with irinotecan monotherapy as a third- or later-line treatment for patients with advanced or recurrent gastric or gastroesophageal cancer (AGC) that has progressed on previous ramucirumab-based chemotherapy.

    METHODS

    Patients age 20 years and older with AGC, who had experienced disease progression during ramucirumab-based chemotherapy, were randomly assigned to receive either ramucirumab plus irinotecan or irinotecan monotherapy. The primary end point was overall survival (OS) expecting a hazard ratio (HR) of 0.77 (a power of 80% and a significance level of one-sided 0.05). Secondary end points included progression-free survival (PFS), response rate, disease control rate (DCR), and safety.

    RESULTS

    Between February 2017 and August 2022, 402 patients in Japan were randomly assigned to receive ramucirumab plus irinotecan (n = 202) or irinotecan monotherapy (n = 200). The median OS was 9.4 months in the combination arm and 8.5 months in the monotherapy arm, with an adjusted HR of 0.91 (95% CI, 0.74 to 1.12; P = .49). PFS was improved (median, 3.8 v 2.8 months; HR, 0.72 [95% CI, 0.59 to 0.89]; P = .002), while the DCR was significantly better (64.4% v 52.1%; P = .03) with the combination therapy. The adverse events of the combination therapy were manageable.

    CONCLUSION

    Adding ramucirumab to irinotecan does not provide a significant advantage in OS over irinotecan alone in patients with AGC who have progressed during ramucirumab-containing chemotherapy.
  • Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
    Kentaro Sawada; Riu Yamashita; Shunsuke A. Sakai; Satoshi Horasawa; Ayumu Yoshikawa; Takao Fujisawa; Shigenori Kadowaki; Ken Kato; Makoto Ueno; Eiji Oki; Yoshito Komatsu; Tatsuyuki Chiyoda; Yosuke Horita; Hisateru Yasui; Tadamichi Denda; Hironaga Satake; Taito Esaki; Taroh Satoh; Naoki Takahashi; Kentaro Yamazaki; Nobuhisa Matsuhashi; Tomohiro Nishina; Hiroyuki Takeda; Koushiro Ohtsubo; Takashi Ohta; Akihito Tsuji; Masahiro Goto; Takeshi Kato; Hideaki Bando; Katsuya Tsuchihara; Yoshiaki Nakamura; Takayuki Yoshino
    Cancer Research Communications, 5, 5, 857, 870, American Association for Cancer Research (AACR), 2025年05月01日, [査読有り], [筆頭著者]
    英語, 研究論文(学術雑誌), Abstract

    Although the gut microbiome is associated with cancer development and progression, little is known about the effects of the gut microbiome landscape and the efficacy of immune checkpoint inhibitors (ICI) across cancer types. We investigated the association between the microbiome, clinical features, and ICI efficacy across cancer types in a large nationwide screening project for solid tumors. Among 2,180 patients with advanced solid tumors enrolled in the SCRUM-Japan MONSTAR-SCREEN between October 2019 and September 2021, in the chemotherapy-naïve cohort (n = 817), a high prevalence of oral bacteria was observed in patients using proton pump inhibitors (PPI) and those with upper gastrointestinal cancers, particularly postoperative patients with gastric or pancreatic cancer. Among patients treated with ICIs (n = 333), a high abundance of sequence variants in the gut microbiome was not significantly associated with ICI efficacy across cancer types (HR = 0.94; 95% confidence interval, 0.73–1.21). However, high oral bacteria in feces significantly correlated with a shorter progression-free survival compared with low oral bacteria (median, 4.34 vs. 6.97 months; HR = 1.38; 95% confidence interval, 1.07–1.78). Notably, in patients using PPIs, a higher proportion of oral bacteria influenced progression-free survival outcomes of ICI treatment (median, 3.15 vs. 2.04 months; P = 0.08), unlike in PPI nonusers (median, 7.13 vs. 5.55 months; P = 0.74). This study of the gut microbiome has unveiled significant insights into its landscape and potential impact on ICI efficacy. It highlights that the abundance of oral bacteria in feces may play a critical role in diminishing ICI efficacy among patients using PPIs.

    Significance:

    As part of the MONSTAR-SCREEN, a prospective nationwide project for patients with solid tumors, we found that although gut microbiome diversity does not consistently predict ICI efficacy across cancer types, a high level of oral bacteria in the gut is linked to reduced ICI effectiveness, especially in patients using PPIs. These findings highlight the potential clinical impact of microbiome variations on cancer treatment outcomes.
  • Gut microbiome associated with PARP inhibitor efficacy in patients with ovarian cancer
    Mika Okazawa-Sakai; Shunsuke A. Sakai; Ichinosuke Hyodo; Satoshi Horasawa; Kentaro Sawada; Takao Fujisawa; Yasuko Yamamoto; Shogen Boku; Yoh Hayasaki; Masanori Isobe; Daisuke Shintani; Kosei Hasegawa; Tomomi Egawa-Takata; Kimihiko Ito; Kei Ihira; Hidemichi Watari; Kazuhiro Takehara; Hiroshi Yagi; Kiyoko Kato; Tatsuyuki Chiyoda; Kenichi Harano; Yoshiaki Nakamura; Riu Yamashita; Takayuki Yoshino; Daisuke Aoki
    Journal of Gynecologic Oncology, 36, 3, XMLink, 2025年, [査読有り]
    英語, 研究論文(学術雑誌)
  • Artificial Intelligence–Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2–Amplified Metastatic Colorectal Cancer: Exploratory Analysis of Phase II TRIUMPH Trial
    Mitsuho Imai; Yoshiaki Nakamura; Sangwon Shin; Wataru Okamoto; Takeshi Kato; Taito Esaki; Ken Kato; Yoshito Komatsu; Satoshi Yuki; Toshiki Masuishi; Tomohiro Nishina; Kentaro Sawada; Akihiro Sato; Takeshi Kuwata; Riu Yamashita; Takao Fujisawa; Hideaki Bando; Chan-Young Ock; Satoshi Fujii; Takayuki Yoshino
    JCO Precision Oncology, 9, American Society of Clinical Oncology (ASCO), 2025年01月, [査読有り]
    英語, 研究論文(学術雑誌), PURPOSE

    Human epidermal growth factor receptor 2 (HER2)–targeted therapies have shown promise in treating HER2 -amplified metastatic colorectal cancer (mCRC). Identifying optimal biomarkers for treatment decisions remains challenging. This study explores the potential of artificial intelligence (AI) in predicting treatment responses to trastuzumab plus pertuzumab (TP) in patients with HER2 -amplified mCRC from the phase II TRIUMPH trial.

    MATERIALS AND METHODS

    AI-powered HER2 quantification continuous score (QCS) and tumor microenvironment (TME) analysis were applied to the prescreening cohort (n = 143) and the TRIUMPH cohort (n = 30). AI analyzers determined the proportions of tumor cells (TCs) with HER2 staining intensity and the densities of various cells in TME, examining their associations with clinical outcomes of TP.

    RESULTS

    The AI-powered HER2 QCS for HER2 immunohistochemistry (IHC) achieved an accuracy of 86.7% against pathologist evaluations, with a 100% accuracy for HER2 IHC 3+ patients. Patients with ≥50% of TCs showing HER2 3+ staining intensity (AI-H3-high) exhibited significantly prolonged progression-free survival (PFS; median PFS, 4.4 v 1.4 months; hazard ratio [HR], 0.12 [95% CI, 0.04 to 0.38]) and overall survival (OS; median OS, 16.5 v 4.1 months; HR, 0.13 [95% CI, 0.05 to 0.38]) compared with the AI-H3-low (<50% group). Stratification among patients with AI-H3-high included TME-high (all lymphocyte, fibroblast, and macrophage densities in the cancer stroma above the median) and TME-low (anything below the median), showing a median PFS of 1.3 and 5.6 months for TME-high and TME-low respectively, with an HR of 0.04 (95% CI, 0.01 to 0.19) for AI-H3-high with TME-low compared with AI-H3-low.

    CONCLUSION

    AI-powered HER2 QCS and TME analysis demonstrated potential in enhancing treatment response predictions in patients with HER2 -amplified mCRC undergoing TP therapy.
  • A multicenter, prospective, phase II trial of second‐line aflibercept plus FOLFIRI in patients with metastatic colorectal cancer refractory to an anti‐ EGFR antibody: HGCSG1801
    Hiroshi Nakatsumi; Yoshito Komatsu; Kazuaki Harada; Yasuyuki Kawamoto; Satoshi Yuki; Kentaro Sawada; Atsushi Ishiguro; Susumu Sogabe; Takayuki Ando; Yusuke Sasaki; Ayumu Yoshikawa; Michio Nakamura; Masayoshi Dazai; Miki Tateyama; Osamu Muto; Masahito Kotaka; Tamotsu Sagawa; Tetsuhito Muranaka; Kazuteru Hatanaka; Ryo Takagi; Yu Sakata
    International Journal of Cancer, 155, 12, 2223, 2231, Wiley, 2024年08月14日, [査読有り]
    英語, 研究論文(学術雑誌), Abstract

    Aflibercept (AFL) plus FOLFIRI prolongs overall survival (OS) in patients with metastatic colorectal cancer (mCRC). However, there is limited evidence on the efficacy and safety of AFL plus FOLFIRI previously treated with anti‐epidermal growth factor receptor (EGFR) agents. Therefore, we conducted a prospective open‐label phase II trial evaluating the efficacy and safety of AFL plus FOLFIRI in Japanese patients with mCRC failing a prior oxaliplatin‐based chemotherapy plus an anti‐EGFR agent. AFL (4 mg/kg iv) followed by FOLFIRI (irinotecan 180 mg/m 2 , leucovorin 200 mg/m 2 iv, bolus 5‐fluorouracil [5‐FU] 400 mg/m 2 , and infusional 5‐FU 2400 mg/m 2 /46 h) was given every 2 weeks until progression or unacceptable toxicities. The primary endpoint was progression‐free survival (PFS) rate at 6 months. Forty three patients were enrolled between November 2019 and October 2022. The primary endpoint was met: 6‐month PFS rate was 58.8% (90% confidence interval [CI], 45.7%–72.0%). Median PFS and OS were 7.3 months (95% CI, 5.5–11.0 months) and 18.8 months (95% CI, 12.9–26.6 months), respectively. The overall response rate was 20.9% (95% CI, 10.0–36.0%) and disease control rate was 88.4% (95% CI, 74.9–96.1%). The main grade ≥3 adverse events included hypertension (62.8%), neutropenia (55.8%), leukopenia (25.6%), febrile neutropenia (11.6%), fatigue (9.3%), anorexia (9.3%), proteinuria (9.3%), and diarrhea (7.0%). No deaths and no new safety signals with a causal relation to the study treatment were observed. This study suggests that AFL plus FOLFIRI shows a high response rate and a manageable safety profile in Japanese patients with mCRC who failed prior oxaliplatin‐based chemotherapy plus an anti‐EGFR agent.
  • Japanese Society of Medical Oncology clinical guidelines: Molecular testing for colorectal cancer treatment, 5th edition
    Hideaki Bando; Kyoko Yamaguchi; Seiichiro Mitani; Kentaro Sawada; Saori Mishima; Keigo Komine; Yoshinaga Okugawa; Waki Hosoda; Hiromichi Ebi
    Cancer Science, 115, 3, 1014, 1021, Wiley, 2024年01月23日, [査読有り]
    英語, 研究論文(学術雑誌), Abstract

    Molecular testing to determine optimal therapies is essential for managing patients with colorectal cancer (CRC). In October 2022, the Japanese Society of Medical Oncology published the 5th edition of the Molecular Testing Guideline for Colorectal Cancer Treatment. In this guideline, in patients with unresectable CRC, RAS/BRAF V600E mutational and mismatch repair tests are strongly recommended prior to first‐line chemotherapy to select optimal first‐ and second‐line therapies. In addition, HER2 testing is strongly recommended because the pertuzumab plus trastuzumab combination is insured after fluoropyrimidine, oxaliplatin, and irinotecan in Japan. Circulating tumor DNA (ctDNA)‐based RAS testing is also strongly recommended to assess the indications for the readministration of anti‐EGFR antibodies. Both tissue‐ and ctDNA‐based comprehensive genomic profiling tests are strongly recommended to assess the indications for targeted molecular drugs, although they are currently insured in patients with disease progression after receiving standard chemotherapy (or in whom disease progression is expected in the near future). Mutational and mismatch repair testing is strongly recommended for patients with resectable CRC, and RAS/BRAF V600E mutation testing is recommended to estimate the risk of recurrence. Mutational and mismatch repair and BRAF testing are also strongly recommended for screening for Lynch syndrome. Circulating tumor DNA‐based minimal residual disease (MRD) testing is strongly recommended for estimating the risk of recurrence based on clinical evidence, although MRD testing was not approved in Japan at the time of the publication of this guideline.
  • Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma: A Multicenter, Retrospective Cohort Study (HGCSG2101)
    Kazuaki Harada; Takahiro Yamamura; Osamu Muto; Michio Nakamura; Susumu Sogabe; Kentaro Sawada; Shintaro Nakano; Masataka Yagisawa; Tetsuhito Muranaka; Masayoshi Dazai; Miki Tateyama; Yoshimitsu Kobayashi; Sosuke Kato; Kazuteru Hatanaka; Yasuyuki Kawamoto; Satoshi Yuki; Yuh Sakata; Naoya Sakamoto; Yoshito Komatsu
    Journal of Clinical Medicine, 12, 4, 1596, 1596, MDPI AG, 2023年02月17日, [査読有り]
    英語, 研究論文(学術雑誌), The effects of UGT1A1 gene polymorphisms or prior irinotecan treatment on treatment outcomes of nanoliposomal-irinotecan plus 5-fluorouracil/leucovorin (nal-IRI+5-FU/LV) in patients with unresectable pancreatic ductal adenocarcinoma (PDAC) are not established. This multicenter, retrospective cohort study compared treatment outcomes in patients with UGT1A1*1/*1 and those with UGT1A1*1/*6 or *1/*28 genotypes. We also analyzed the impact of prior irinotecan treatment on survival outcomes in 54 patients treated with nal-IRI+5-FU/LV. Comparable effectiveness was found regardless of the UGT1A1 genotypes. While no significant differences were found, grade ≥3 neutropenia and febrile neutropenia were more frequent in patients with UGT1A1*1/*6 or *1/*28 than in those with UGT1A1*1/*1 genotypes (grade ≥3 neutropenia, 50.0% vs. 30.8%, p = 0.24; febrile neutropenia, 9.1% vs. 0.0%, p = 0.20, respectively). No significant difference in progression-free survival (PFS) and overall survival (OS) was observed between irinotecan-naïve-patients and other patients. However, irinotecan-resistant patients showed significantly shorter PFS (hazard ratio (HR) 2.83, p = 0.017) and OS (HR 2.58, p = 0.033) than other patients. Our study indicated that patients with UGT1A1*1/*6 or *1/*28 may be prone to neutropenia, though further study is needed. The survival benefit of nal-IRI+5-FU/LV could be maintained in patients without disease progression after irinotecan therapy.
  • Feasibility of edoxaban for asymptomatic cancer-associated thrombosis in Japanese patients with gastrointestinal cancer: ExCAVE study
    Michio Nakamura; Atsushi Ishiguro; Masayoshi Dazai; Yasuyuki Kawamoto; Satoshi Yuki; Susumu Sogabe; Ayumu Hosokawa; Kentaro Sawada; Osamu Muto; Naoki Izawa; Koji Nakashima; Yoshiki Horie; Masataka Yagisawa; Shinya Kajiura; Takayuki Ando; Yosuke Mitsuhashi; Yu Sunakawa; Yasuka Kikuchi; Yoshito Komatsu
    BMC Cancer, 22, 1, Springer Science and Business Media LLC, 2022年12月16日, [査読有り]
    英語, 研究論文(学術雑誌), Abstract

    Background

    Although initial therapy with a parenteral anticoagulant is required before edoxaban, this strategy is frequently avoided in actual clinical practice because of its complexity. This study assessed the feasibility of edoxaban without initial heparin usage for asymptomatic cancer-associated thrombosis (CAT) in Japanese patients with gastrointestinal cancer (GIC) at high risk of bleeding.

    Methods

    In this multicenter prospective feasibility study conducted at 10 Japanese institutions, patients with active GIC who developed accidental asymptomatic CAT during chemotherapy were recruited. Edoxaban was orally administered once daily without initial parenteral anticoagulant therapy within 3 days after detecting asymptomatic CAT. The primary outcome was the incidence of major bleeding (MB) or clinically relevant non-major bleeding (CRNMB) during the first 3 months of edoxaban administration.

    Results

    Of the 54 patients enrolled from October 2017 to September 2020, one was excluded because of a misdiagnosis of CAT. In the remaining 53 patients, the primary outcome occurred in six patients (11.3%). MB occurred in four patients (7.5%), including gastrointestinal bleeding in three patients and intracranial hemorrhage in one patient. CRNMB occurred in two patients (3.8%), including bleeding from the stoma site and genital bleeding in one patient each. There were no deaths attributable to bleeding, and all patients who experienced MB or CRNMB recovered.

    Conclusions

    The risk of bleeding after edoxaban without heparin pretreatment was acceptable, demonstrating new treatment options for asymptomatic CAT in patients with GIC.
  • Fecal microbiota in patients with a stoma decreases anaerobic bacteria and alters taxonomic and functional diversities
    Shunsuke A. Sakai; Masato Aoshima; Kentaro Sawada; Satoshi Horasawa; Ayumu Yoshikawa; Takao Fujisawa; Shigenori Kadowaki; Tadamichi Denda; Nobuhisa Matsuhashi; Hisateru Yasui; Masahiro Goto; Kentaro Yamazaki; Yoshito Komatsu; Ryota Nakanishi; Yoshiaki Nakamura; Hideaki Bando; Yamato Hamaya; Shun-Ichiro Kageyama; Takayuki Yoshino; Katsuya Tsuchihara; Riu Yamashita
    Frontiers in Cellular and Infection Microbiology, 12, Frontiers Media SA, 2022年09月14日, [査読有り]
    英語, 研究論文(学術雑誌), Colorectal cancer (CRC) is one of the most common malignant diseases. Generally, stoma construction is performed following surgery for the resection of the primary tumor in patients with CRC. The association of CRC with the gut microbiota has been widely reported, and the gut microbiota is known to play an important role in the carcinogenesis, progression, and treatment of CRC. In this study, we compared the microbiota of patients with CRC between with and without a stoma using fecal metagenomic sequencing data from SCRUM-Japan MONSTAR-SCREEN, a joint industry-academia cancer research project in Japan. We found that the composition of anaerobes was reduced in patients with a stoma. In particular, the abundance of Alistipes, Akkermansia, Intestinimonas, and methane-producing archaea decreased. We also compared gene function (e.g., KEGG Orthology and KEGG pathway) and found that gene function for methane and short-chain fatty acids (SCFAs) production was underrepresented in patients with a stoma. Furthermore, a stoma decreased Shannon diversity based on taxonomic composition but increased that of the KEGG pathway. These results suggest that the feces of patients with a stoma have a reduced abundance of favorable microbes for cancer immunotherapy. In conclusion, we showed that a stoma alters the taxonomic and functional profiles in feces and may be a confounding factor in fecal microbiota analysis.
  • Definitive chemoradiotherapy has comparable survival outcomes to esophagectomy in patients with clinical T1N0M0 esophageal squamous cell carcinoma: real-world data
    Kentaro Sawada; Daisuke Kotani; Hiroki Yukami; Saori Mishima; Hisashi Fujiwara; Tomohiro Kadota; Keiichiro Nakajo; Yusuke Yoda; Masaki Nakamura; Hidehiro Hojo; Tomonori Yano; Takeo Fujita; Takashi Kojima
    International Journal of Clinical Oncology, 27, 8, 1279, 1288, Springer Science and Business Media LLC, 2022年07月02日, [査読有り], [筆頭著者]
    英語, 研究論文(学術雑誌)
  • Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603
    Yasuyuki Kawamoto; Satoshi Yuki; Kentaro Sawada; Michio Nakamura; Osamu Muto; Susumu Sogabe; Yoshiaki Shindo; Atsushi Ishiguro; Atsushi Sato; Yasushi Tsuji; Masayoshi Dazai; Hiroyuki Okuda; Takashi Meguro; Kazuaki Harada; Mari Sekiguchi; Kazufumi Okada; Yoichi M Ito; Yuh Sakata; Naoya Sakamoto; Yoshito Komatsu
    The Oncologist, 27, 8, e642, e649, Oxford University Press (OUP), 2022年05月17日, [査読有り]
    英語, 研究論文(学術雑誌), Abstract

    Background

    Ramucirumab is a human IgG1 monoclonal vascular endothelial growth factor receptor-2 antibody that inhibits tumor cell growth and affects the tumor cell microenvironment. We assessed the efficacy and safety of ramucirumab plus irinotecan combination therapy as second-line treatment in patients with previously treated advanced gastric cancer.

    Materials and Methods

    Patients with advanced gastric cancer refractory or intolerant to primary chemotherapy were included. Ramucirumab 8 mg/kg plus irinotecan 150 mg/m2 combination therapy was administered every 2 weeks. The primary endpoint was progression-free survival rate at 6 months and secondary endpoints were overall survival, progression-free survival, response rate, safety, and dose intensity for each drug.

    Results

    Thirty-five patients were enrolled between January 2018 and September 2019. The progression-free survival rate at 6 months was 26.5% [95%CI, 13.2%–41.8%, P = .1353)]. Median progression-free and overall survivals were 4.2 months (95%CI, 2.5-5.4 months) and 9.6 months (95%CI, 6.4-16.6 months), respectively. The overall response rate was 25.9% (95%CI, 11.1-36.3%) and disease control rate was 85.2% (95%CI, 66.3-95.8%). Grade ≥3 adverse events that occurred in &gt;10% of patients included neutropenia, leucopenia, anemia, anorexia, and febrile neutropenia. No death or new safety signals with a causal relation to the study treatment were observed.

    Conclusion

    Although the primary endpoint was not achieved statistically, combination therapy of ramucirumab plus irinotecan showed anticancer activity and a manageable safety profile for second-line treatment of patients with advanced gastric cancer.
  • Long-term clinical outcome after endoscopic resection of esophageal squamous cell carcinoma invading the muscularis mucosae without lymphovascular invasion
    Daiki Sato; Tomohiro Kadota; Atsushi Inaba; Keiichiro Nishihara; Kenji Takashima; Keiichiro Nakajo; Kentaro Sawada; Daisuke Kotani; Hisashi Fujiwara; Yusuke Yoda; Takashi Kojima; Takeo Fujita; Satoshi Fujii; Tomonori Yano
    Gastrointestinal Endoscopy, 95, 4, 634, 641.e3, Elsevier BV, 2022年04月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer
    Ken Ito; Satoshi Yuki; Hiroshi Nakatsumi; Yasuyuki Kawamoto; Kazuaki Harada; Shintaro Nakano; Rika Saito; Takayuki Ando; Kentaro Sawada; Masataka Yagisawa; Atsushi Ishiguro; Masayoshi Dazai; Ichiro Iwanaga; Kazuteru Hatanaka; Atsushi Sato; Ryusuke Matsumoto; Yoshiaki Shindo; Miki Tateyama; Tetsuhito Muranaka; Masaki Katagiri; Isao Yokota; Yuh Sakata; Naoya Sakamoto; Yoshito Komatsu
    Supportive Care in Cancer, 30, 6, 5351, 5359, Springer Science and Business Media LLC, 2022年03月15日, [査読有り]
    英語, 研究論文(学術雑誌), Abstract

    Purpose

    Dysgeusia is an adverse event caused by chemotherapy. Although retrospective studies have shown zinc administration improves dysgeusia, there have been no prospective studies. The present study examined effects of zinc therapy on dysgeusia in patients with gastrointestinal cancer.

    Methods

    This multicenter, prospective, observational study enrolled patients with dysgeusia during chemotherapy treatment. Patients received no intervention (control), polaprezinc p.o., or zinc acetate hydrate p.o., and serum zinc levels were measured at 0 (baseline), 6, and 12 weeks. Dysgeusia was assessed using CTCAE v5.0 and subjective total taste acuity (STTA) criteria using questionnaires at baseline and 12 weeks.

    Results

    From February 2020 to June 2021, 180 patients were enrolled from 17 institutes. There were no differences in mean baseline serum zinc levels among the groups (67.3, 66.6, and 67.5 μg/dL in the no intervention, polaprezinc, and zinc acetate hydrate groups, respectively. P = 0.846). The changes in mean serum zinc levels after 12 weeks were − 3.8, + 14.3, and + 46.6 μg/dL, and the efficacy rates of dysgeusia were 33.3%, 36.8%, and 34.6% using CTCAE and 33.3%, 52.6%, 32.7% using STTA in the no intervention, polaprezinc, and zinc acetate hydrate groups, respectively. The STTA scores improved in all groups, with significant improvement observed in the polaprezinc group compared with the no intervention group (P = 0.045).

    Conclusion

    There was no significant correlation between the degree of serum zinc elevation and improvement in dysgeusia, suggesting that polaprezinc, but not zinc acetate hydrate, was effective in improving chemotherapy-induced dysgeusia.

    Trial registration.

    UMIN000039653. Date of registration: March 2, 2020.
  • The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective study
    Takeshi Kawakami; Toshiki Masuishi; Yasuyuki Kawamoto; Hirofumi Go; Kyoko Kato; Ryosuke Kumanishi; Kentaro Sawada; Satoshi Yuki; Kouji Yamamoto; Yoshito Komatsu; Kei Muro; Kunihiro Fushiki; Hiromichi Shirasu; Kentaro Yamazaki
    Cancer Medicine, 11, 11, 2184, 2192, Wiley, 2022年02月19日, [査読有り]
    英語, 研究論文(学術雑誌), Abstract

    Background

    The development of chemotherapy and treatment strategies for metastatic colorectal cancer (mCRC) have provided patients with significant survival benefits. Currently, molecular targeting agents and late‐line treatment with regorafenib and trifluridine/tipiracil (FTD/TPI) are available. However, the impact of this increase in drug availability on overall survival (OS) in mCRC remains a clinical question.

    Methods

    We retrospectively collected data on consecutive mCRC patients who were treated at three institutions in Japan. We divided the patients into three cohorts: patients who initiated first‐line treatment from Jan 2005 to Dec 2006 (cohort A: only cytotoxic drugs available), Jan 2007 to Dec 2011 (cohort B: molecular targeting drugs available), and Jan 2012 to Sep 2016 (cohort C: late‐line treatment available).

    Results

    A total of 1409 consecutive patients were analyzed. The median survival time (MST) in cohorts A, B, and C was 18.6, 25.4, and 26.4 months, respectively. The hazard ratio (HR) for cohort B versus A was 0.81 (95% CI 0.68–0.97), for cohort C versus A was 0.74 (95% CI 0.61–0.89), and for cohort C versus B was 0.92 (0.81–1.03). The median number of administered drugs (range) was 3 (1–5) in cohort A, 4 (1–7) in cohort B, and 4 (1–7) in cohort C. The increase in drug availability extended the MST from 15.5 months in patients treated with ≤3 drugs to 36.0–37.3 months in patients treated with six to seven drugs.

    Conclusion

    The development of chemotherapy including late‐line treatments could improve the prognosis of mCRC patients.
  • Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial
    Yoshiaki Nakamura; Wataru Okamoto; Takeshi Kato; Taito Esaki; Ken Kato; Yoshito Komatsu; Satoshi Yuki; Toshiki Masuishi; Tomohiro Nishina; Hiromichi Ebi; Kentaro Sawada; Hiroya Taniguchi; Nozomu Fuse; Shogo Nomura; Makoto Fukui; Seiko Matsuda; Yasutoshi Sakamoto; Hiroshi Uchigata; Kana Kitajima; Naomi Kuramoto; Takashi Asakawa; Steve Olsen; Justin I. Odegaard; Akihiro Sato; Satoshi Fujii; Atsushi Ohtsu; Takayuki Yoshino
    Nature Medicine, 27, 11, 1899, 1903, Springer Science and Business Media LLC, 2021年11月11日, [査読有り]
    英語, 研究論文(学術雑誌), Abstract

    The applicability of circulating tumor DNA (ctDNA) genotyping to inform enrollment of patients with cancer in clinical trials has not been established. We conducted a phase 2 trial to evaluate the efficacy of pertuzumab plus trastuzumab for metastatic colorectal cancer (mCRC), with human epidermal growth factor receptor 2 (HER2) amplification prospectively confirmed by tumor tissue or ctDNA analysis (UMIN000027887). HER2 amplification was confirmed in tissue and/or ctDNA in 30 patients with mCRC. The study met the primary endpoint with a confirmed objective response rate of 30% in 27 tissue-positive patients and 28% in 25 ctDNA-positive patients, as compared to an objective response rate of 0% in a matched real-world reference population treated with standard-of-care salvage therapy. Post hoc exploratory analyses revealed that baseline ctDNA genotyping of HER2 copy number and concurrent oncogenic alterations adjusted for tumor fraction stratified patients according to efficacy with similar accuracy to tissue genotyping. Decreased ctDNA fraction 3 weeks after treatment initiation associated with therapeutic response. Pertuzumab plus trastuzumab showed similar efficacy in patients with mCRC with HER2 amplification in tissue or ctDNA, showing that ctDNA genotyping can identify patients who benefit from dual-HER2 blockade as well as monitor treatment response. These findings warrant further use of ctDNA genotyping in clinical trials for HER2-amplified mCRC, which might especially benefit patients in first-line treatment.
  • Long-term clinical outcomes of patients diagnosed with pT1a-muscularis mucosae with lymphovascular invasion or pT1b after endoscopic resection for cT1N0M0 esophageal squamous cell carcinoma
    Tomohiro Kadota; Daiki Sato; Atsushi Inaba; Keiichiro Nishihara; Kenji Takashima; Keiichiro Nakajo; Hiroki Yukami; Saori Mishima; Kentaro Sawada; Daisuke Kotani; Hisashi Fujiwara; Masaki Nakamura; Hidehiro Hojo; Yusuke Yoda; Takashi Kojima; Takeo Fujita; Tomonori Yano
    Esophagus, 19, 1, 153, 162, Springer Science and Business Media LLC, 2021年08月22日, [査読有り]
    英語, 研究論文(学術雑誌)
  • The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study
    Keigo Chida; Daisuke Kotani; Toshiki Masuishi; Takeshi Kawakami; Yasuyuki Kawamoto; Kyoko Kato; Kunihiro Fushiki; Kentaro Sawada; Ryosuke Kumanishi; Hiromichi Shirasu; Yuki Matsubara; Satoshi Yuki; Yoshito Komatsu; Kentaro Yamazaki; Takayuki Yoshino
    The Oncologist, 26, 10, 845, 853, Oxford University Press (OUP), 2021年07月07日, [査読有り]
    英語, 研究論文(学術雑誌), Abstract

    Background

    KRAS is one of the most frequently mutated oncogenes in colorectal cancer (CRC). Recently, a novel therapy targeting KRAS G12C mutation has demonstrated promising activities for corresponding advanced solid tumors, including metastatic CRC (mCRC). However, the prognostic impact of the KRAS G12C mutation remains unclear in patients with mCRC.

    Materials and Methods

    We retrospectively reviewed medical records of patients with mCRC who received first-line chemotherapy between January 2005 and December 2017 at four large oncology facilities in Japan. Survival outcomes were compared between patients with KRAS G12C and those with non-G12C mutations.

    Results

    Among 2,457 patients with mCRC, 1,632 met selection criteria, and of these, 696 had KRAS exon 2 mutations, including 45 with KRAS G12C mutation tumors. Patient characteristics were not significantly different between the KRAS G12C and non-G12C groups. At a median follow-up of 64.8 months, patients with the KRAS G12C mutation showed significantly shorter first-line progression-free survival (PFS; median, 9.4 vs. 10.8 months; p = .015) and overall survival (OS; median, 21.1 vs. 27.3 months; p = .015) than those with non-G12C mutations. Multivariate analysis also showed that KRAS G12C mutation was significantly associated with shorter PFS (hazard ratio [HR], 1.43; 95% confidence interval [CI], 1.04–1.96, p = .030) and OS (HR, 1.42; 95% CI, 1.01–2.00; p = .044).

    Conclusion

    We demonstrate that, compared with non-G12C mutations, KRAS G12C mutation is significantly correlated with shorter first-line PFS and OS. These findings indicate the relevance of a stratified treatment targeting KRAS G12C mutation in mCRC.

    Implications for Practice

    Among patients with KRAS exon 2 mutated metastatic colorectal cancer (mCRC), median progression-free survival (PFS) and overall survival (OS) were 9.4 and 21.1 months, respectively, for G12C mutation and 10.8 and 27.3 months, respectively, for patients with non-G12C mutations, indicating significantly shorter PFS (hazard ratio [HR], 1.47; 95% confidence interval [CI], 1.08–2.01; p = .015) and OS (HR, 1.50; 95% CI, 1.08–2.08; p = .015) in patients with G12C mutation than in those with non-G12C mutations. Furthermore, multivariate analysis showed that KRAS G12C mutation was independently associated with shorter first-line PFS and OS. Thus, these findings underscore the relevance of a stratified treatment targeting KRAS G12C mutation in mCRC.
  • A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403)
    Yasuyuki Kawamoto; Hiroshi Nakatsumi; Kazuaki Harada; Tetsuhito Muranaka; Atsushi Ishiguro; Yoshimitsu Kobayashi; Hideyuki Hayashi; Satoshi Yuki; Kentaro Sawada; Masataka Yagisawa; Shintaro Nakano; Naoya Sakamoto; Yoshito Komatsu
    The Oncologist, 26, 10, e1675, e1682, Oxford University Press (OUP), 2021年06月21日, [査読有り]
    英語, 研究論文(学術雑誌), Abstract

    Lessons Learned

    Background

    OX-IRIS is a new combination therapy of oxaliplatin, irinotecan, and S-1 for unresectable pancreatic ductal adenocarcinoma (PDAC), which may be beneficial because S-1 is administered orally and continuous infusion of 5-fluorouracil (5-FU) is not needed.

    Methods

    Patients who had not received prior therapy for unresectable PDAC were enrolled. Adenocarcinoma or adenosquamous histology was required. Oxaliplatin and irinotecan were administered on days 1 and 15; S-1 was administered orally twice a day on days 1–14, followed by 14 days of rest (one cycle). Primary endpoints were dose-limiting toxicity (DLT) and maximum tolerated dose (MTD). Secondary endpoints were safety, overall response rate (ORR), progression-free survival (PFS), and overall survival (OS).

    Results

    In level 0 (oxaliplatin, 85 mg/m2; irinotecan, 100 mg/m2; S-1, 80 mg/m2), two of five patients experienced DLT. In level −1 (oxaliplatin, 65 mg/m2; irinotecan, 100 mg/m2; S-1, 80 mg/m2), DLT could not be evaluated in two of eight patients because one cycle was not completed; one of the remaining six patients experienced DLT. Anemia, thrombocytopenia, fatigue, nausea, anorexia, diarrhea, and peripheral sensory neuropathy were seen frequently in levels 0 and −1. ORR was 30% in levels 0 and −1. Median progression-free survival and median overall survival were 4.1 months (95% confidence interval [CI], 0.0–8.9 months) and 13.7 months (95% CI, 4.8–22.6 months), respectively.

    Conclusion

    MTD of OX-IRIS therapy was estimated to be level 0, and the recommended dose (RD) for future trial was level −1.
  • CIRCULATE‐Japan: Circulating tumor DNA–guided adaptive platform trials to refine adjuvant therapy for colorectal cancer
    Hiroya Taniguchi; Yoshiaki Nakamura; Daisuke Kotani; Hiroki Yukami; Saori Mishima; Kentaro Sawada; Hiromichi Shirasu; Hiromichi Ebi; Takeharu Yamanaka; Alexey Aleshin; Paul R. Billings; Matthew Rabinowitz; Eiji Oki; Ichiro Takemasa; Takeshi Kato; Masaki Mori; Takayuki Yoshino
    Cancer Science, 112, 7, 2915, 2920, Wiley, 2021年06月07日, [査読有り]
    英語, 研究論文(学術雑誌), Abstract

    Adjuvant chemotherapy has reduced the risk of tumor recurrence and improved survival in patients with resected colorectal cancer. Potential utility of circulating tumor DNA (ctDNA) prior to and post surgery has been reported across various solid tumors. We initiated a new type of adaptive platform trials to evaluate the clinical benefits of ctDNA analysis and refine precision adjuvant therapy for resectable colorectal cancer, named CIRCULATE‐Japan including three clinical trials. The GALAXY study is a prospectively conducted large‐scale registry designed to monitor ctDNA for patients with clinical stage II to IV or recurrent colorectal cancer who can undergo complete surgical resection. The VEGA trial is a randomized phase III study designed to test whether postoperative surgery alone is noninferior to the standard therapy with capecitabine plus oxaliplatin for 3 months in patients with high‐risk stage II or low‐risk stage III colon cancer if ctDNA status is negative at week 4 after curative surgery in the GALAXY study. The ALTAIR trial is a double‐blind, phase III study designed to establish the superiority of trifluridine/tipiracil as compared with placebo in patients with resected colorectal cancer who show circulating tumor–positive status in the GALAXY study. Therefore, CIRCULATE‐Japan encompasses both “de‐escalation” and “escalation” trials for ctDNA‐negative and ‐positive patients, respectively, and helps to answer whether measuring ctDNA postoperatively has prognostic and/or predictive value. Our ctDNA‐guided adaptive platform trials will accelerate clinical development toward further precision oncology in the field of adjuvant therapy. Analysis of ctDNA status could be utilized as a predictor of risk stratification for recurrence and to monitor the effectiveness of adjuvant chemotherapy. ctDNA is a promising, noninvasive tumor biomarker that can aid in tumor monitoring throughout disease management.
  • Prognostic Value and Molecular Landscape of HER2 Low-Expressing Metastatic Colorectal Cancer
    Masataka Yagisawa; Kentaro Sawada; Yoshiaki Nakamura; Satoshi Fujii; Satoshi Yuki; Yoshito Komatsu; Takayuki Yoshino; Naoya Sakamoto; Hiroya Taniguchi
    Clinical Colorectal Cancer, 20, 2, 113, 120.e1, Elsevier BV, 2021年06月, [査読有り]
    英語, 研究論文(学術雑誌)
  • International Harmonization of Provisional Diagnostic Criteria for ERBB2-Amplified Metastatic Colorectal Cancer Allowing for Screening by Next-Generation Sequencing Panel
    Satoshi Fujii; Anthony M. Magliocco; Jihun Kim; Wataru Okamoto; Jeong Eun Kim; Kentaro Sawada; Yoshiaki Nakamura; Scott Kopetz; Woong-Yang Park; Katsuya Tsuchihara; Tae Won Kim; Kanwal Raghav; Takayuki Yoshino
    JCO Precision Oncology, 4, 6, 19, American Society of Clinical Oncology (ASCO), 2020年11月, [査読有り]
    研究論文(学術雑誌), PURPOSE

    ERBB2 amplification (human epidermal growth factor receptor 2 positivity [HER2+]) in metastatic colorectal cancer (mCRC) has important therapeutic implications that necessitate the need for accurate diagnostics. The study purpose was to establish and validate harmonized diagnostic criteria for HER2+ mCRC among 3 groups (GI-SCREEN-Japan, NCTN-SWOG-USA, and Korea).

    PATIENTS AND METHODS

    We assessed HER2 status by immunohistochemistry (IHC), ERBB2/CEP17 ratio, gene copy number (GCN) by fluorescence in situ hybridization (FISH), and copy number variation (CNV) using two targeted next-generation sequencing (NGS) panels. Tumor samples from 475 and 16 patients with mCRC in exploratory and validation cohorts, respectively, were used for cross-validation of the NGS panels.

    RESULTS

    Consensus diagnostic criteria among the 3 groups for HER2+ mCRC were established as follows: IHC 3+ or IHC 2+ and ERBB2/CEP17 ratio by FISH ≥ 2.0, tumor content > 10% for surgically resected specimens, and necessary tumor content not defined for biopsy specimens. The median GCN and CNV for HER2+ patients were 10.9 and 27.7 compared with 2.5 ( P < .0001) and 3.5 ( P < .0001), respectively, in HER2-negative patients. These findings were validated in a validation cohort (GCN, 16.2 v 2.4 [ P = .0002]; CNV, 42.5 v 2.0 [ P = .0003]). GCN correlated with CNV in both cohorts (exploratory, r = 0.90; validation, r = 0.97; P < .0001). CNV in cross-validation of the 2 NGS panels also showed a strong correlation ( r = 0.98; P < .0001). CNV in patients who fulfilled the consensus criteria was > 4.0 in all, which demonstrates the accuracy of the IHC/FISH criteria and cross-validation of NGS panels.

    CONCLUSION

    We have established and verified harmonized diagnostic criteria for HER2+ and demonstrated consistency between IHC/FISH and CNV determined by NGS in mCRC.
  • The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer
    Yohei Kubota; Akihito Kawazoe; Akinori Sasaki; Saori Mishima; Kentaro Sawada; Yoshiaki Nakamura; Daisuke Kotani; Yasutoshi Kuboki; Hiroya Taniguchi; Takashi Kojima; Toshihiko Doi; Takayuki Yoshino; Genichiro Ishii; Takeshi Kuwata; Kohei Shitara
    Clinical Cancer Research, 26, 14, 3784, 3790, American Association for Cancer Research (AACR), 2020年07月15日, [査読有り]
    英語, 研究論文(学術雑誌), Abstract

    Purpose:

    We evaluated the association between molecular subtypes of advanced gastric cancer (AGC) and the efficacy of standard chemotherapy or immune checkpoint inhibitors.

    Experimental Design:

    Patients with AGC who received systemic chemotherapy from October 2015 to July 2018 with available molecular features were analyzed. We investigated the efficacy of standard first- (fluoropyrimidine + platinum ± trastuzumab) and second-line (taxanes ± ramucirumab) chemotherapy, and subsequent anti–PD-1 therapy in patients with four molecular subtypes: MMR-D (mismatch repair deficient), EBV+, HER2+, and all negative.

    Results:

    410 patients were analyzed: MMR-D 5.9%, EBV+ 4.1%, HER2+ 13.7%, and all negative 76.3%. In 285 patients who received standard first-line chemotherapy, the median progression-free survival (PFS) times were 4.2, 6.0, 7.5, and 7.6 months and the objective response rates (ORR) were 31%, 62%, 60%, and 49% in MMR-D, EBV+, HER2+, and all-negative subtypes, respectively. Multivariate analysis showed shorter PFS in MMR-D versus all-negative patients [HR, 1.97; 95% CIs, 1.09–3.53; P = 0.022]. In second-line setting, there were no significant differences in efficacy. In 110 patients who received anti–PD-1 therapy, median PFS times were 13.0, 3.7, 1.6, and 1.9 months and the ORRs were 58%, 33%, 7%, and 13%, respectively. Twelve patients with MMR-D received subsequent anti–PD-1 therapy and showed longer PFS compared with that in 10 (83%) patients who received earlier-line chemotherapy.

    Conclusions:

    MMR-D might result in shorter PFS with first-line chemotherapy for AGC. Subsequent anti–PD-1 therapy achieved higher ORR and longer PFS than prior chemotherapy in most patients with MMR-D, supporting the earlier use of immune checkpoint inhibitors.
  • Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer
    Akinori Sasaki; Akihito Kawazoe; Testuya Eto; Mashiro Okunaka; Saori Mishima; Kentaro Sawada; Yoshiaki Nakamura; Daisuke Kotani; Yasutoshi Kuboki; Hiroya Taniguchi; Takashi Kojima; Toshihiko Doi; Takayuki Yoshino; Tetsuo Akimoto; Kohei Shitara
    ESMO Open, 5, 4, e000775, e000775, Elsevier BV, 2020年07月, [査読有り]
    英語, 研究論文(学術雑誌), Background

    The efficacy and safety of chemotherapy (CTx) after anti-PD-1 therapy in patients with advanced gastric cancer (AGC) remains unclear.

    Methods

    Medical records of consecutive patients with AGC treated with both CTx (taxanes plus ramucirumab, taxanes monotherapy or irinotecan) and anti-PD-1 therapy from June 2015 to April 2019 were retrospectively analysed. Patients were divided into two groups based on prior exposure to anti-PD-1 therapy: anti-PD-1-exposed and anti-PD-1-naïve groups. CTx-related outcomes were compared between two groups in the overall population and each CTx population.

    Results

    In total, 233 patients (67 anti-PD-1-exposed, 166 anti-PD-1-naïve) were included. In the overall population, the objective response rate (ORR) to CTX was 44.6% in the anti-PD-1-exposed group and 19.6% in the anti-PD-1-naïve group (p=0.001); the median progression-free survivals (PFS) were 3.7 months and 3.3 months (HR=0.82, p=0.20), respectively. Among patients receiving taxanes plus ramucirumab (n=149), ORR (60.6% vs 20.0%, p<0.001) and median PFS (4.8 vs 3.4 months, p=0.004, HR=0.56) were significantly better in the anti-PD-1-exposed group (n=39) compared with the anti-PD-1-naïve group (n=110). These differences were not observed in patients receiving taxane monotherapy (n=34) or irinotecan (n=50). CTx after anti-PD-1 therapy showed no severe or unexpected adverse events.

    Conclusions

    Prior anti-PD-1 therapy might increase tumour response to taxanes plus ramucirumab without unexpected adverse events, which warrants further investigations in a large cohort.
  • Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancer
    Akinori Sasaki; Yoshiaki Nakamura; Yosuke Togashi; Hirofumi Kuno; Hidehiro Hojo; Shunichiro Kageyama; Naoki Nakamura; Kenji Takashima; Tomohiro Kadota; Yusuke Yoda; Saori Mishima; Kentaro Sawada; Daisuke Kotani; Akihito Kawazoe; Yasutoshi Kuboki; Hiroya Taniguchi; Takashi Kojima; Toshihiko Doi; Takayuki Yoshino; Tomonori Yano; Tatsushi Kobayashi; Tetsuo Akimoto; Hiroyoshi Nishikawa; Kohei Shitara
    Gastric Cancer, 23, 5, 893, 903, Springer Science and Business Media LLC, 2020年03月16日, [査読有り]
    英語, 研究論文(学術雑誌)
  • Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer
    Takahiro Ishii; Akihito Kawazoe; Akinori Sasaki; Saori Mishima; Sawada Kentaro; Yoshiaki Nakamura; Daisuke Kotani; Yasutoshi Kuboki; Hiroya Taniguchi; Takashi Kojima; Toshihiko Doi; Takayuki Yoshino; Takeshi Kuwata; Genichiro Ishii; Kohei Shitara
    Therapeutic Advances in Medical Oncology, 12, SAGE Publications, 2020年01月, [査読有り]
    英語, 研究論文(学術雑誌), Background:

    The use of nivolumab or irinotecan as the third-line treatment for patients with advanced gastric cancer (AGC) remains controversial.

    Methods:

    This study analyzed patients with AGC treated with nivolumab or irinotecan (nivolumab group or irinotecan group, respectively) from May 2016 to April 2019 following two or more previous lines of chemotherapy. Univariate survival analysis was conducted to identify the clinical and molecular factors associated with progression-free survival (PFS).

    Results:

    A total of 156 patients (74 treated with nivolumab and 82 treated with irinotecan) were analyzed. The median PFS was 1.9 months in both treatment groups. The median overall survival (OS) was 7.2 and 6.2 months in the nivolumab and irinotecan groups, respectively. Eastern Cooperative Oncology Group performance status of 1 or more, liver metastasis, a large tumor size at baseline, and HER2-positive status were associated with a worse PFS in the nivolumab group compared with the irinotecan group. The nivolumab group showed a significantly longer PFS (median 3.1 versus 2.0 months) and OS (median 12.9 versus 7.8 months) than the irinotecan group in patients with 0 or 1 of these factors, whereas the irinotecan group showed a significantly longer PFS (median 1.0 versus 1.8 months) and a trend of longer OS (median 3.9 versus 6.1 months) in patients with ⩾2 of these factors.

    Conclusions:

    Some clinical and molecular factors were associated with outcomes following nivolumab or irinotecan as the third- or later-line treatment in patients with AGC. These factors must be considered while selecting an optimal treatment option.
  • Development of HER2 -targeted Therapies for Gastrointestinal Cancer
    Kentaro Sawada; Yoshiaki Nakamura; Kohei Shitara
    European Oncology & Haematology, 16, 1, 29, 29, Touch Medical Media, Ltd., 2020年, [査読有り], [招待有り], [筆頭著者]
    研究論文(学術雑誌),

  • HER2-targeted therapy should be shifted towards an earlier line for patients with anti-EGFR-therapy naïve, HER2-amplified metastatic colorectal cancer
    Yoshiaki Nakamura; Kentaro Sawada; Satoshi Fujii; Takayuki Yoshino
    ESMO Open, 4, 3, e000530, e000530, Elsevier BV, 2019年, [査読有り]
    英語, 研究論文(学術雑誌)
  • Clinical practice guidance for next‐generation sequencing in cancer diagnosis and treatment (Edition 1.0)
    Kuniko Sunami; Hideaki Takahashi; Katsuya Tsuchihara; Masayuki Takeda; Tatsuya Suzuki; Yoichi Naito; Kazuko Sakai; Hirotoshi Dosaka‐Akita; Chikashi Ishioka; Yasuhiro Kodera; Manabu Muto; Toshifumi Wakai; Kentaro Yamazaki; Wataru Yasui; Hideaki Bando; Yumi Fujimoto; Shota Fukuoka; Kenichi Harano; Akihito Kawazoe; Gen Kimura; Shigehiro Koganemaru; Takahiro Kogawa; Daisuke Kotani; Yasutoshi Kuboki; Hiroshi Matsumoto; Shingo Matsumoto; Saori Mishima; Yoshiaki Nakamura; Kentaro Sawada; Sumito Shingaki; Kohei Shitara; Kumiko Umemoto; Shigeki Umemura; Kayo Yasuda; Takayuki Yoshino; Noboru Yamamoto; Kazuto Nishio
    Cancer Science, 109, 9, 2980, 2985, Wiley, 2018年09月05日, [査読有り]
    英語, 研究論文(学術雑誌), In Japan, the social (medical) health‐care system is on the way to being developed to advance personalized medicine through the implementation of cancer genomic medicine, known as “cancer clinical sequencing,” which uses a next‐generation sequencer. However, no Japanese guidance for cancer genomic testing exists. Gene panel testing can be carried out to help determine patient treatment, confirm diagnosis, and evaluate prognostic predictions of patients with mainly solid cancers for whom no standard treatment is available. This guidance describes how to utilize gene panel testing according to the type of cancer: childhood cancer, rare cancer, carcinoma of unknown primary, and other cancers. The level of evidence classification for unified use in Japan is also detailed. This guidance establishes the basic principles of the quality control of specimens, requirements of medical institutions, informed consent, handling of data during the postanalysis stage, and treatment options based on the evidence level. In Japan, gene panel testing for cancer treatment and diagnosis is recommended to comply with this guidance. This is a collaborative work of the Japanese Society of Medical Oncology, Japan Society of Clinical Oncology, and the Japanese Cancer Association.
  • Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer
    Kentaro Sawada; Yoshiaki Nakamura; Takeharu Yamanaka; Yasutoshi Kuboki; Daisuke Yamaguchi; Satoshi Yuki; Takayuki Yoshino; Yoshito Komatsu; Naoya Sakamoto; Wataru Okamoto; Satoshi Fujii
    Clinical Colorectal Cancer, 17, 3, 198, 205, Elsevier BV, 2018年09月, [査読有り], [筆頭著者]
    研究論文(学術雑誌)
  • The Clinical Landscape of Circulating Tumor DNA in Gastrointestinal Malignancies
    Kentaro Sawada; Daisuke Kotani; Hideaki Bando
    Frontiers in Oncology, 8, Frontiers Media SA, 2018年07月16日, [査読有り], [招待有り], [筆頭著者]
    研究論文(学術雑誌)
  • Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer
    Yasuyuki Kawamoto; Yoshito Komatsu; Satoshi Yuki; Kentaro Sawada; Tetsuhito Muranaka; Kazuaki Harada; Hiroshi Nakatsumi; Hiraku Fukushima; Atsushi Ishiguro; Masayoshi Dazai; Kazuteru Hatanaka; Michio Nakamura; Ichiro Iwanaga; Minoru Uebayashi; Susumu Sogabe; Yoshimitsu Kobayashi; Takuto Miyagishima; Kota Ono; Naoya Sakamoto; Yuh Sakata
    BMC Cancer, 17, 1, Springer Science and Business Media LLC, 2017年12月08日, [査読有り]
    英語, 研究論文(学術雑誌)
  • Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer
    Tetsuhito Muranaka; Masaki Kuwatani; Yoshito Komatsu; Kentaro Sawada; Hiroshi Nakatsumi; Yasuyuki Kawamoto; Satoshi Yuki; Yoshimasa Kubota; Kimitoshi Kubo; Shuhei Kawahata; Kazumichi Kawakubo; Hiroshi Kawakami; Naoya Sakamoto
    Journal of Gastrointestinal Oncology, 8, 3, 566, 571, AME Publishing Company, 2017年06月, [査読有り]
    研究論文(学術雑誌)
  • Efficacy and Safety of Bolus 5-Fluorouracil and L-Leucovorin as Salvage Chemotherapy for Oral Fluoropyrimidine-Resistant Unresectable or Recurrent Gastric Cancer: A Single Center Experience
    Tetsuhito Muranaka; Satoshi Yuki; Yoshito Komatsu; Kentaro Sawada; Kazuaki Harada; Yasuyuki Kawamoto; Hiroshi Nakatsumi; Naoya Sakamoto
    Journal of Gastric Cancer, 16, 3, 177, 177, The Korean Gastric Cancer Association, 2016年, [査読有り]
    研究論文(学術雑誌)
■ その他活動・業績